PreBiomicsPMT A metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseases
- Coordinator
- Prebiomics SRL, Italy
- Runs
- 1 May 2023 to 30 April 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €2.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101113004
What the project is doing
In the project's own words, from its summary on CORDIS.
About 20M dental implants are performed globally per year. Implant market, valued at 3.6B in 2020, is growing at a CAGR of 11%. Unfortunately, microbiome-biofilm-associated diseases can affect dental implants, compromising oral and systemic health. More than 50% of implant patients develop mucositis, an inflammation of the soft tissues, which may lead to peri-implantitis, a severe infection affecting soft and hard tissues that can lead to implant loss.
Currently, there are no reliable tools to assess disease severity and risk of disease progression; and the dentist can only prescribe empirical therapies without knowing the composition of the triggering peri-implant plaque microbiome. At PreBiomics, we developed a precision-medicine test that characterises the microbial composition of the plaque biofilm collected in the area surrounding the implant. In 10 years of research, we have shown that specific bacteria's presence is key to predicting the infection's severity and progression.
PreBiomicsPMT will develop a test using metagenomics, and an AI algorithm, which will enable the implementation of monitoring and diagnosis and provide treatment recommendations for each patient based on the bacterial composition of their plaque microbiome. Based on the results of the ERC POCs PB3P, this EIC-Transition project aims at automating the workflow using a robotic solution to reduce the costs of the service and speed up the results, building an extensive database that will be used to create an antibiotic resistance panel and further develop our decision support system (DSS) for dentists, finally, conducting a validation study to prove the predictive power of our DSS.
Alongside the technical development, we will define the IPR management plan to protect the knowledge we continuously generate, study in-depth the dental implants market and the needs and expectations of our customers and investors and elaborate a robust business plan to allow proper exploitation of our product.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Prebiomics SRL | Trento | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI